Ignite Creation Date:
2024-05-06 @ 6:44 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05766748
Status:
RECRUITING
Last Update Posted:
2024-06-14
First Post:
2023-02-24
Brief Title:
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
Sponsor:
Cantex Pharmaceuticals
Organization:
Cantex Pharmaceuticals
Organization Data
Organization:
Cantex Pharmaceuticals
Class:
INDUSTRY
Study ID:
CAN-201 MPC
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cantex Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None